ライフサイエンスコーパス: hemoglobin F

1 d expression of the antisickling hemoglobin, hemoglobin F.

2 n was obtained by demonstrating that natural hemoglobin F(1), which is specifically acetylated at Gly

3 Greater hemoglobin F and erythropoietin each independently predi

4 Chronic dosing and sustained increases in hemoglobin F and total hemoglobin levels may be possible

5 the association equilibrium constant between hemoglobins F and A lessened progressively.

6 iated with faster eGFR decline, but elevated hemoglobins F and A(2) were renoprotective.

7 red to the pK(a) 7.1 value of Val-1(beta) of hemoglobins F and A, respectively.

8 nd can in part be predicted by age, level of hemoglobin F, and platelet count.

9 The hemolysis-lowering and hemoglobin F-augmenting effects of hydroxyurea may exert

10 ing the production of cells containing fetal hemoglobin (F cells).

11 Hemoglobin F correlated positively with erythropoietin e

12 protonation of the gamma-chain N-terminus of hemoglobin F from pH 9.0 to 8.0 is therefore suggested a

13 Given a gradient relationship between fecal hemoglobin (f-Hb) concentration and colorectal neoplasia

14 udies have shown that individuals with fecal hemoglobin (f-Hb) concentrations just below the positivi

15 e the mechanisms that increase the levels of hemoglobin F (HbF) in the blood of patients with severe

16 sion, inflammatory pathways, upregulation of hemoglobin F, hemoglobin polymerization and sickling, co

17 Hydroxyurea and higher hemoglobin F improve the clinical course and survival in

18 In conclusion, increase in hemoglobin F in sickle cell disease may be associated wi

19 producing a modest increase in the level of hemoglobin F in symptomatic patients with this disease s

20 , despite the significantly higher levels of hemoglobin F in the former, suggesting that efforts dire

21 Tetrameric fetal hemoglobin F in the liganded state was found to dissocia

22 This may in part reflect the lower level of hemoglobin F in this condition compared with other forms

23 agnosis included age less than 2 years and a hemoglobin F level of less than 10%.

24 otypes showed earlier presentation and lower hemoglobin F levels in patients with c-Cbl mutations.

25 receiving hydroxyurea; they also had higher hemoglobin F (P < .001) and erythropoietin (P = .012) le

26 low dose is frequently prescribed to induce hemoglobin F production in patients with sickle cell and

27 sease was treated with hydroxyurea to induce hemoglobin F production since 2007 without incident.

28 Greater levels of erythropoietin or hemoglobin F were independently associated with higher t